Now on
The Profits of Nonprofit
The Profits of Nonprofit
The surprising results when drug development and altruism collide. [TheScientist]
Rare Partners announces a three parties alliance for thalassemia
Rare Partners announces a three parties alliance for the use of rapamycin in thalassemic patients, based on the research carried out by Professor Roberto Gambari and coworkers at the University of Ferrara.
Rare Partners and Fondazione Umberto Di Mario signed an agreement in the field of type 1 diabetes
Rare Partners and Fondazione Umberto Di Mario signed an agreement in the field of type 1 diabetes.
Haemoglobin Disorders: laboratory diagnosis and clinical management
Haemoglobin Disorders: laboratory diagnosis and clinical management. 1-2 April, 2011 - Brussels, Belgium
Optimal Role of Patient Organizations in Drug Development
Optimal Role of Patient Organizations in Drug Development. 24 March, 2011 - Amsterdam, The Netherlands